Health science reports · 2026
Clinical Use of Combined First-Trimester Screening Test for Aneuploidy in A Low-Income Setting: Retrospective Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Diress Tesfaye, Wondafrash Mekitie, Gudu Wondimu, Abdosh Abdulfetah Abdulkadir, Sium Abraham Fessehaye
Аннотация
BACKGROUND: Although combined first trimester screening is effective at detecting fetal chromosomal anomalies which are trisomy 21, 18 and 13, there is scarce data on its practice and practice in low-income countries. This study presents data on clinical use of combined first trimester prenatal screening tests among pregnant women in a Sub-Saharan setting.
METHODS: This retrospective study was conducted over 7 years between July 2016 and June 2023 at St. Paul's Hospital Millennium Medical College (Ethiopia). Risk assessment was done with Snibe 2000 software using maternal age, nuchal translucency, PAPP-A, β-hCG and other maternal characteristics. Statistical analysis was done using SPSS version 22. Fishers exact and Man Whitney U test were done as appropriate, and P-value less than 0.05 was used to present significance of the results.
RESULTS: A total of 141 patients were included in the final analysis. Overall high-risk cases for aneuploidy based on the combined test was 24.8%. Screening positive for aneuploidy had an association with increased nuchal translucency [median (IQR) = 2.1 (1.7, 2.5) for screening negative vs 2.9 (2.4, 2.9) for screening positive test, p-value = 0.021] and low PAPP-A values ≤ 0.05 MoM (1 (5%) for negative and 5 (56%) for positive, p-value = 0.005).
CONCLUSION: The prevalence of screening positive for high-risk aneuploidy in this study was higher than in previous reports which may be due to the fact that the study population is primary high-risk women. Nuchal translucency and low PAPP-A values were associated with screening positive for aneuploidy. Combined first trimester screening is feasible and effective for detecting fetal chromosomal anomalies in low-income settings. Laboratory capacity for performing serum analytes and genetic testing, and availability of nuchal translucency ultrasound services should acted up on for creating a wider access to such vital prenatal genetic screening and testing services.
METHODS: This retrospective study was conducted over 7 years between July 2016 and June 2023 at St. Paul's Hospital Millennium Medical College (Ethiopia). Risk assessment was done with Snibe 2000 software using maternal age, nuchal translucency, PAPP-A, β-hCG and other maternal characteristics. Statistical analysis was done using SPSS version 22. Fishers exact and Man Whitney U test were done as appropriate, and P-value less than 0.05 was used to present significance of the results.
RESULTS: A total of 141 patients were included in the final analysis. Overall high-risk cases for aneuploidy based on the combined test was 24.8%. Screening positive for aneuploidy had an association with increased nuchal translucency [median (IQR) = 2.1 (1.7, 2.5) for screening negative vs 2.9 (2.4, 2.9) for screening positive test, p-value = 0.021] and low PAPP-A values ≤ 0.05 MoM (1 (5%) for negative and 5 (56%) for positive, p-value = 0.005).
CONCLUSION: The prevalence of screening positive for high-risk aneuploidy in this study was higher than in previous reports which may be due to the fact that the study population is primary high-risk women. Nuchal translucency and low PAPP-A values were associated with screening positive for aneuploidy. Combined first trimester screening is feasible and effective for detecting fetal chromosomal anomalies in low-income settings. Laboratory capacity for performing serum analytes and genetic testing, and availability of nuchal translucency ultrasound services should acted up on for creating a wider access to such vital prenatal genetic screening and testing services.